Jeff Jones
Stock Analyst at Oppenheimer
(4.48)
# 1,047
Out of 4,382 analysts
267
Total ratings
39.4%
Success rate
14.6%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ODTX Odyssey Therapeutics | Initiated Coverage: Buy | $40 | $16.43 | +143.46% | 1 | Jun 2, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $13 | $3.03 | +329.04% | 31 | Jun 1, 2026 | |
| AVBP ArriVent BioPharma | Reiterated: Buy | $50 | $30.35 | +64.74% | 8 | Jun 1, 2026 | |
| MDWD MediWound | Maintained: Buy | $34 → $32 | $14.18 | +125.67% | 5 | May 28, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterated: Buy | $33 | $11.12 | +196.76% | 17 | May 15, 2026 | |
| CMMB Chemomab Therapeutics | Maintained: Buy | $25 | $1.77 | +1,312.43% | 22 | May 15, 2026 | |
| PTHS Pelthos Therapeutics | Reiterated: Buy | $62 → $66 | $25.55 | +158.32% | 8 | May 15, 2026 | |
| ALMS Alumis | Reiterated: Buy | $55 | $19.06 | +188.56% | 12 | May 15, 2026 | |
| PMVP PMV Pharmaceuticals | Maintained: Buy | $6 → $5 | $1.12 | +346.43% | 16 | May 13, 2026 | |
| PHVS Pharvaris | Reiterated: Buy | $50 | $31.09 | +60.82% | 10 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $4.36 | +129.36% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $7 | $4.15 | +68.67% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $41 → $40 | $12.54 | +218.95% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 | $28.29 | +203.99% | 7 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53 → $57 | $7.56 | +653.97% | 20 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.59 | - | 20 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $74.13 | +61.88% | 12 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $3.40 | +370.59% | 4 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $20 | $5.47 | +265.97% | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.15 | - | 22 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.63 | n/a | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.82 | n/a | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.40 | n/a | 5 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $2.20 | n/a | 4 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.50 | n/a | 4 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $3.55 | n/a | 3 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 2 | Jul 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.0111 | n/a | 1 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $55.69 | n/a | 1 | Jun 22, 2021 |
Odyssey Therapeutics
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $16.43
Upside: +143.46%
Perspective Therapeutics
Jun 1, 2026
Reiterated: Buy
Price Target: $13
Current: $3.03
Upside: +329.04%
ArriVent BioPharma
Jun 1, 2026
Reiterated: Buy
Price Target: $50
Current: $30.35
Upside: +64.74%
MediWound
May 28, 2026
Maintained: Buy
Price Target: $34 → $32
Current: $14.18
Upside: +125.67%
Corvus Pharmaceuticals
May 15, 2026
Reiterated: Buy
Price Target: $33
Current: $11.12
Upside: +196.76%
Chemomab Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $25
Current: $1.77
Upside: +1,312.43%
Pelthos Therapeutics
May 15, 2026
Reiterated: Buy
Price Target: $62 → $66
Current: $25.55
Upside: +158.32%
Alumis
May 15, 2026
Reiterated: Buy
Price Target: $55
Current: $19.06
Upside: +188.56%
PMV Pharmaceuticals
May 13, 2026
Maintained: Buy
Price Target: $6 → $5
Current: $1.12
Upside: +346.43%
Pharvaris
May 13, 2026
Reiterated: Buy
Price Target: $50
Current: $31.09
Upside: +60.82%
May 8, 2026
Reiterated: Buy
Price Target: $10
Current: $4.36
Upside: +129.36%
May 8, 2026
Reiterated: Buy
Price Target: $6 → $7
Current: $4.15
Upside: +68.67%
May 8, 2026
Maintained: Buy
Price Target: $41 → $40
Current: $12.54
Upside: +218.95%
Apr 20, 2026
Maintained: Buy
Price Target: $86
Current: $28.29
Upside: +203.99%
Mar 10, 2026
Reiterated: Buy
Price Target: $53 → $57
Current: $7.56
Upside: +653.97%
Mar 2, 2026
Rated: Hold
Price Target: n/a
Current: $2.59
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $120
Current: $74.13
Upside: +61.88%
Aug 15, 2025
Maintained: Buy
Price Target: $17 → $16
Current: $3.40
Upside: +370.59%
Aug 14, 2025
Maintained: Buy
Price Target: $19 → $20
Current: $5.47
Upside: +265.97%
Aug 8, 2025
Maintained: Hold
Price Target: n/a
Current: $1.15
Upside: -
Oct 29, 2024
Rated: Hold
Price Target: n/a
Current: $6.63
Upside: n/a
Aug 14, 2024
Maintained: Hold
Price Target: n/a
Current: $3.82
Upside: n/a
Nov 30, 2023
Maintained: Buy
Price Target: n/a
Current: $2.40
Upside: n/a
Nov 10, 2023
Maintained: Hold
Price Target: n/a
Current: $2.20
Upside: n/a
Nov 7, 2023
Maintained: Buy
Price Target: n/a
Current: $1.50
Upside: n/a
Apr 28, 2023
Rated: Buy
Price Target: n/a
Current: $3.55
Upside: n/a
Jul 20, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Sep 30, 2021
Reiterated: Hold
Price Target: n/a
Current: $0.0111
Upside: n/a
Jun 22, 2021
Maintained: Buy
Price Target: $37
Current: $55.69
Upside: n/a